180 related articles for article (PubMed ID: 29524829)
41. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
42. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
[TBL] [Abstract][Full Text] [Related]
43. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Seeger H; Wallwiener D; Mueck AO
Horm Metab Res; 2003 Feb; 35(2):76-80. PubMed ID: 12734785
[TBL] [Abstract][Full Text] [Related]
44. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
45. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.
Pierson-Mullany LK; Lange CA
Mol Cell Biol; 2004 Dec; 24(24):10542-57. PubMed ID: 15572662
[TBL] [Abstract][Full Text] [Related]
46. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice.
Raafat AM; Hofseth LJ; Li S; Bennett JM; Haslam SZ
Endocrinology; 1999 Jun; 140(6):2570-80. PubMed ID: 10342844
[TBL] [Abstract][Full Text] [Related]
47. Hormone replacement therapy and estrogen-dependent cancers.
Birkhäuser M
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
[TBL] [Abstract][Full Text] [Related]
48. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.
de Lignières B; de Vathaire F; Fournier S; Urbinelli R; Allaert F; Le MG; Kuttenn F
Climacteric; 2002 Dec; 5(4):332-40. PubMed ID: 12626212
[TBL] [Abstract][Full Text] [Related]
49. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
50. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
Talley LI; Grizzle WE; Waterbor JW; Brown D; Weiss H; Frost AR
Int J Cancer; 2002 Mar; 98(1):118-27. PubMed ID: 11857395
[TBL] [Abstract][Full Text] [Related]
51. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
52. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
53. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium.
Arnett-Mansfield RL; DeFazio A; Mote PA; Clarke CL
J Clin Endocrinol Metab; 2004 Mar; 89(3):1429-42. PubMed ID: 15001645
[TBL] [Abstract][Full Text] [Related]
54. Estrogen plus progestin increase superoxide dismutase and total antioxidant capacity in postmenopausal women.
Unfer TC; Figueiredo CG; Zanchi MM; Maurer LH; Kemerich DM; Duarte MM; Konopka CK; Emanuelli T
Climacteric; 2015 Jun; 18(3):379-88. PubMed ID: 25236970
[TBL] [Abstract][Full Text] [Related]
55. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women.
Vural P; Akgul C; Canbaz M
Pharmacol Res; 2006 Oct; 54(4):298-302. PubMed ID: 16879975
[TBL] [Abstract][Full Text] [Related]
56. Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer.
Lamb CA; Fabris VT; Jacobsen B; Molinolo AA; Lanari C
Endocr Relat Cancer; 2018 Jul; ():. PubMed ID: 29991638
[TBL] [Abstract][Full Text] [Related]
57. The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth.
Nakamura M; Takakura M; Fujii R; Maida Y; Bono Y; Mizumoto Y; Zhang X; Kiyono T; Kyo S
Cancer Lett; 2013 Aug; 336(1):68-75. PubMed ID: 23603247
[TBL] [Abstract][Full Text] [Related]
58. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
Sartorius CA; Harvell DM; Shen T; Horwitz KB
Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
[TBL] [Abstract][Full Text] [Related]
59. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
60. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
Birrell SN; Butler LM; Harris JM; Buchanan G; Tilley WD
FASEB J; 2007 Aug; 21(10):2285-93. PubMed ID: 17413000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
